ABSTRACT Classical prodrug design often represents a nonspecific chemical approach to mask undesirable drug properties such as limited bioavailability, lack of site specificity, and chemical instability. On the other hand, targeted prodrug design represents a new strategy for directed and efficient drug delivery. Particularly, targeting the prodrugs to a specific enzyme or a specific membrane transporter, or both, has potential as a selective drug delivery system in cancer chemotherapy or as an efficient oral drug delivery system. Site-selective targeting with prodrugs can be further enhanced by the simultaneous use of gene delivery to express the requisite enzymes or transporters. This review highlights evolving strategies in targeted prodrug design, including antibody-directed enzyme prodrug therapy, genedirected enzyme prodrug therapy, and peptide transporter-associated prodrug therapy.
INTRODUCTION
Many therapeutic drugs have undesirable properties that may become pharmacological, pharmaceutical, or pharmacokinetic barriers in clinical drug application. Among the various approaches to minimize the undesirable drug properties while retaining the desirable therapeutic activity, the chemical approach using drug derivatization offers perhaps the highest flexibility and has been demonstrated as an important means of improving drug efficacy.
The prodrug approach, a chemical approach using reversible derivatives, can be useful in the optimization of the clinical application of a drug. The prodrug approach gained attention as a technique for improving drug therapy in the early 1970s. Numerous prodrugs have been designed and developed since then to overcome pharmaceutical and pharmacokinetic barriers in clinical drug application, such as low oral drug absorption, lack of site specificity, chemical instability, toxicity, and poor patient acceptance (bad taste, odor, pain at injection site, etc.) (1).
The term "prodrug" or "proagent" was first introduced by Albert (2) to signify pharmacologically inactive chemical derivatives that could be used to alter the physicochemical properties of drugs, in a temporary manner, to increase their usefulness and/or to decrease associated toxicity. Since Albert discussed the concept of prodrugs in the late 1950s, such compounds have also been called "latentiated drugs," "bioreversible derivatives," and "congeners," but "prodrug" is now the most commonly accepted term (3) (4) (5) . Usually, the use of the term implies a covalent link between a drug and a chemical moiety, though some authors also use it to characterize some forms of salts of the active drug molecule. Although there is no strict universal definition for a prodrug itself, and the definition may vary from author to author, generally prodrugs can be defined as pharmacologically inert chemical derivatives that can be converted in vivo to the active drug molecules, enzymatically or nonenzymatically, to exert a therapeutic effect. Ideally, the prodrug should be converted to the original drug as soon as the goal is achieved, followed by the subsequent rapid elimination of the released derivatizing group (5, 6) .
Targeted Prodrug Design
Prodrugs can be designed to target specific enzymes or carriers by considering enzyme-substrate specificity or carrier-substrate specificity in order to overcome various undesirable drug properties. This type of "targeted-prodrug" design requires considerable knowledge of particular enzymes or carrier systems, including their molecular and functional characteristics. Recently, advances in gene cloning and controlled gene expression techniques in mammalian cells allow the elucidation of the molecular nature of enzymes and carrier proteins and make possible more rational design of "targeted-prodrugs."
In this brief review, targeted prodrug design will be discussed in 2 categories: (1) targeting specific enzymes and (2) targeting specific membrane transporters.
Prodrug Design Targeting Enzymes
In prodrug design, enzymes can be recognized as presystemic metabolic sites or prodrug-drug in vivo reconversion sites. Usually, targeting enzymes to reduce the presystemic metabolism is more successfully achieved by irreversible chemical modification rather than by a prodrug approach. Therefore, our discussion focuses on the enzymes as in vivo reconversion targets for prodrugs.
The enzyme-targeted prodrug approach can be broadly used to improve oral drug absorption, as well as site-specific drug delivery. In the case of improving oral drug absorption, gastrointestinal enzymes may be the main targets for prodrug design, and the use of a nutrient moiety as a derivatizing group permits more specific targeting for gastro-intestinal enzymes to improve oral drug absorption (7) . These prodrugs have the additional advantage of producing nontoxic nutrient byproducts when they regenerate the active drugs in vivo. There have been extensive studies on gastrointestinal enzymes, which provide necessary information (eg, enzyme distribution, activity, and specificity) for prodrug design. Because enzyme targeting to improve oral drug absorption has been reviewed elsewhere (7-10), we will discuss enzyme targeting for site-specific drug delivery in the following section.
Strategy for Site-Specific Drug Delivery
The use of prodrugs has been actively pursued to achieve very precise and direct effects at the "site of action," with minimal effect on the rest of the body. Stella and Himmelstein (11, 12) suggested that at least 3 factors should be optimized for the sitespecific delivery of drugs by using the prodrug approach.
1. The prodrug must be readily transported to the site of action, and uptake to the site must be rapid and essentially perfusion rate limited.
2. Once at the site, the prodrug must be selectively cleaved to the active drug relative to its conversion at other sites.
3. Once selectively generated at the site of action, the active drug must be somewhat retained by the tissue.
In the prodrug approach, site-specific drug delivery can be obtained from tissue-specific activation of a prodrug, which is the result of metabolism by an enzyme that is either unique for the tissue or present at a higher concentration (compared with other tissues); thus, it activates the prodrug more efficiently. For example, glycosidase activity of the colonic microflora offers an opportunity to design a colon-specific drug delivery system (13) . Glycoside derivatives are hydrophilic and poorly absorbed from the small intestine, but once they reach the colon, they can be effectively cleaved by bacterial glycosidases to release the free drug or be absorbed by the colonic mucosa. This strategy was evaluated in rats with 2 steroid prodrugs, prednisolone 21β β β β-Dglucoside and dexamethasone 21-β β β β-D-glucoside (13, 14) . Of these glycosidic prodrugs, the dexamethasone glucoside appeared to be the better candidate, with nearly 60% of the orally administered prodrugs reaching the caecum as a free steroid, while orally administered parent steroids were absorbed almost exclusively from the small intestine. L-γ-glutamyl transpeptidase, which is highly concentrated in the kidney. Then, L-dopa was decarboxylated to dopamine by aromatic L-amino acid decarboxylase, which is also highly concentrated in the kidney. The concentration of dopamine in the kidney after administration of L-γ γ γ γ-glutamyl dopa was almost 5 times higher than that after an equivalent dose of L-dopa (15) . This type of site-specific drug delivery has been of particular concern in cancer chemotherapy. Appropriately designed prodrugs have been found to be effective in the treatment of animal tumors possessing high levels of an activating enzyme (17, 18) . However, clinical results were disappointing when it was found that human tumors containing appropriately high levels of the activating enzymes were rare and that the high levels of activating enzymes were not associated with any particular type of tumor (19) . Recently, new therapies have been proposed to overcome this limitation of prodrug therapy. These new approaches are referred to as ADEPT (antibodydirected enzyme prodrug therapy) and GDEPT (gene-directed enzyme prodrug therapy), which attempt the localization of prodrug activation enzymes into specific cancer cells prior to prodrug administration.
ADEPT and GDEPT for Selective Drug Delivery General Concept of ADEPT and GDEPT
Enzymes that activate prodrugs can be directed to human tumor xenografts by conjugating them to tumor-selective monoclonal antibodies (20) (21) (22) (23) (24) (25) . As illustrated in Figure 1 , an antitumor antibody is conjugated to an enzyme not normally present in extracellular fluid or on cell membranes and then these conjugates are localized in the tumor via intravenous infusion. After allowing for the conjugate to clear from the blood, a prodrug is administered that is normally inert but is activated by the enzyme delivered to the tumor. This is the ADEPT procedure. Using different combinations of antibody, enzyme, and prodrug, many classes of human tumor xenograft have been shown to be very sensitive to this procedure, although in most cases they are quite resistant to conventional chemotherapy (20) (21) (22) (23) (24) (25) . Early clinical trials are promising and indicate that ADEPT may become an effective treatment for solid cancers for which tumor-selective antibodies are known (26, 27) .
Tumors have also been targeted with genes encoding prodrug-activating enzymes (28) (29) (30) . This approach can use a viral vector (eg, retroviral or adenoviral) to carry a prodrug-activating enzyme gene into both tumor and normal cells ( Figure 1 ). By linking the foreign gene downstream of tumor-specific transcription units, tumor-specific expression of the foreign enzyme gene can be achieved (28) . This approach has been called virus-directed enzyme prodrug therapy (VDEPT) or more generally genedirected enzyme prodrug therapy (GDEPT) and has shown promising results in laboratory systems (31) (32) (33) . In addition to viral vectors, several methods for delivery of the genes to the target tumor, under the control of tumor-selective promoters, have been proposed using liposomes and cationic lipids (34) .
Strategy of Enzyme Targeting in ADEPT and GDEPT
For the appropriate combination of an enzyme and a prodrug, the choice of enzyme is very important because the appropriate prodrugs can be designed for almost any enzyme. However, enzymes that are monomeric, have low molecular weight, and lack a requirement of glycosylation would be preferable for ease of handling and possible protein modification (35) . In ADEPT and VDEPT, the preferred targets may be the enzymes of nonhuman or nonmammalian origin that could catalyze substrates not normally activated in humans. Thus, in terms of specificity, enzymes from nonhuman sources, particularly those of microbiological origin, are advantageous, and if their immunogenicity is controllable, then specificity may become the overriding consideration (20) . Appropriate combinations of enzymes and prodrugs (Table 1) have been proposed for ADEPT or GDEPT (25, 35) . Some of these combinations are not suitable in any situation, whereas others are more suitable for ADEPT than GDEPT or vice versa. In ADEPT, prodrug activation occurs extracellularly, whereas in GDEPT it occurs intracellularly. Therefore, the choice of enzymes can be different in those 2 approaches. The best enzymes for GDEPT would appear to be monomeric enzymes of bacterial or viral origin with wide substrate specificity (25, 35) . One example is a bacterial nitroreductase that can convert a relatively nontoxic monofunctional alkylating agent into a 10,000 times more cytotoxic difunctional alkylating agent (36) . Because nitroreductases require either NADH or NADPH as an essential reductant, activation of prodrugs can only take place within the cells. Therefore, this enzyme may be a better choice for GDEPT than for ADEPT. In contrast, charged prodrugs that are bifunctional alkylating agents are especially suitable for ADEPT (36) . Because of the charge, they will not enter cells and are nontoxic because the essential target for alkylating agents is intracellular DNA. After extracellular activation of prodrugs in tumor cells, the active drug will be freely diffusible and attain a high intracellular concentration. Thus, alkylating prodrugs activated by β β β β-glucuronidase or carboxypeptidase G2 as glucuronic or glutamic acid derivatives should be excellent for ADEPT (37, 38) .
Prodrug Design Targeting the Membrane Transporters
Although the classical approach to improve membrane permeability of polar drugs uses lipophilic derivatives to increase passive membrane penetration, the targeted prodrug approach uses transporters designed for facilitating membrane transport of polar nutrients such as amino acids and peptides. There is direct and indirect evidence for the participation of carrier-mediated membrane transport mechanisms, where several hydrophilic compounds seem to be absorbed efficiently via specific transporters (39) . Therefore, targeting specific membrane transporters is particularly important when prodrugs are polar or charged. From this point of view, use of intestinal epithelial transporters to facilitate the absorption of appropriately modified drugs seems to be an attractive strategy for improving the bioavailability of poorly absorbed drug molecules. Prodrugs can be designed to resemble the intestinal nutrients structurally and to be absorbed by specific carrier proteins. In this case, prodrugs may have the additional advantage of producing nontoxic nutrient byproducts in which prodrugs are converted to the parent drug molecules. There have been many attempts to improve drug absorption targeting specific membrane transporters, including amino acid, peptide, and glucose transporters. Mizuma et al examined the intestinal absorption of the beta-and alpha-anomers of the glucoside and galactoside of p-nitrophenol to find a more suitable prodrug for poorly absorbed drugs (40, 41) . Using the everted sac technique, pnitrophenyl-β β β β-D-glucopyranoside was found to be actively absorbed by glucose transporters, and its permeation was comparable with that of D-glucose (40) . In addition, glucose conjugates of p-nitrophenol were more permeable across rat everted jejunum than galactose conjugates of p-nitrophenol, which is consistent with the finding that D-glucose has a higher affinity to glucose transporters than Dgalactose (41) . The brain uptake of the potent glycine-NMDA receptor antagonists, such as 7-chlorokynurenic acid and 5,7-dichlorokynurenic acid, was significantly improved by their respective prodrugs, L-4-chlorokynurenine and L-4,6-dichlorokynurenine, which are amino acids (42) . L-4-chlorokynurenine was shown to be rapidly delivered into the brain by the large neutral amino acid transporter of the blood-brain barrier and to be converted intracellularly to its parent drug, 7-chlorokynurenic acid (42) . Furthermore, there have been some reports on prodrug design targeting peptide transporters, including peptidyl derivatives of a-methyldopa and alafosfalin and tripeptidyl prodrugs of foscarnet (43) (44) (45) .
Developing prodrugs targeting specific membrane carriers requires considerable knowledge of the carrier proteins, including their distribution and substrate specificity. Recently, advances in molecular biology have allowed the cloning and controlled expression of carrier proteins and have further elucidated the functional and structural characteristics and regulation of carrier proteins. However, limited information is available on the specific molecular nature of the protein component(s) involved in the transport process at this time. The individual membrane transporters have been reviewed elsewhere (39, 46) . Among various membrane transporters, peptide transporters are attractive targets in prodrug design to improve oral drug absorption because they have several advantages. First, peptide transporters have broad substrate specificity and high capacity (47) . This characteristic is essential for their normal physiologic function. Theoretically, hundreds of dipeptides and thousands of different tripeptides can be generated from 20 amino acids that are chemically and structurally diverse (47) . Therefore, the physiologic advantage of the broad substrate specificity of peptide transporters is obvious. Second, peptide transporters have been more extensively studied than other transporters, and considerable information is available about them. Therefore, structural modifications targeting peptide transporters can be optimized to a much greater degree compared to other transporters. Finally, recent cloning and controlled expression in mammalian cell systems allow us to attempt rational drug design to target the peptide transporters.
PEPT1 and PEPT2 Transporters
Among the transport proteins responsible for translocation of organic solutes across cell membranes in animals, microbes, and plants, protoncoupled peptide transporters represent a distinct protein family with significant sequence homologies in the primary structure of various members of the family (48) . So far, 2 distinct peptide transporters, PEPT1 and PEPT2, have been cloned from animals and humans (49) (50) (51) (52) .
A general characterization of the structural requirements for peptide transporters has been based on uptake, transport, and competitive inhibition experiments. Recently, direct evidence has been provided through the cloning and functional expression of PEPT 1 and PEPT 2 in mammalian cells (49) (50) (51) (52) . In general, peptide transporters have broad substrate requirements and tolerate diverse chemical modification. In addition to the endogenous peptides, various therapeutic drugs, including nonpeptidyl drugs, can be recognized as substrates by peptide transporters. As shown in Figure 2 , β β β β-lactam antibiotics, ACE inhibitors, renin inhibitors, and bestatin are well-known substrates for peptide transporters (39, 53, 54) and possess peptide-like chemical structures with a peptide bond, an Nterminal α α α α-amino group, and a C-terminal carboxyl group. Substitution of an N-terminal α α α α-amino group or a C-terminal carboxyl group of the peptidyl substrates may significantly reduce the affinity for the peptide transport system (55-57), but these groups are still recognized as substrates of peptide transporters. For example, without having an Nterminal α α α α-amino group, peptidyl prodrugs (eg, α α α α-methyldopa-L-phenylalanine), β β β β-lactam antibiotics (eg, cefixime or cefdinir), and ACE inhibitors (eg, captopril, enalapril, quinapril, or benazepril) have been shown to be transported via the intestinal peptide transport system (43, 55, (58) (59) (60) (61) . Also, thyrotropin-releasing hormone and some renin inhibitors lacking a free C-terminal carboxyl group are reported as the substrates of peptide transporters (62, 63) . Therefore, an N-terminal α α α α-amino group and a C-terminal carboxyl group do not appear to be critical requirements for the peptide transporters, although modification of these groups generally diminishes the substrate affinity to the transporters.
Several studies have indicated that the intestinal and renal peptide transporters are stereoselective (64) (65) (66) . Peptidomimetic drugs as well as peptides containing L-amino acids interact with peptide transporters with greater affinity than do those containing D-amino acids. In addition, a D-amino acid at the N-terminal end of a peptide may have a greater effect on transport than one at the carboxyl terminal end (67) .
Until recently, the presence of a peptide bond in the substrate has been considered as a prerequisite for recognition by peptide transporters. However, recent findings on the nonpeptidyl substrates of peptide transporters such as arpharmenine A (68,69), 4-aminophenylacetic acid (70) , and amino acid ester prodrugs of acyclovir and zidovudine (AZT) (71, 72) strongly challenge the obligatory need for a peptide bond (Figure 2 ). Arphamenine A, an Arg-Phe analogue without a peptide bond, appeared to be the substrate of peptide transporters in Caco-2 cells, as well as renal brush border membrane vesicles (68, 69) . In addition, using renal brush border membrane vesicles and Xenopus oocytes expressing PEPT1, Temple et al demonstrated that 4-aminophenylacetic acid, a small nonpeptidyl drug, was translocated by peptide transporters (70) . These studies on the nonpeptidyl substrates of peptide transporters suggest that a peptide bond is not a prerequisite for recognition by peptide transporters. Recently, Han et al successfully demonstrated the prodrug approach targeting the peptide transporters with nonpeptidyl prodrugs to improve oral drug absorption of polar nucleosides (71, 72) . These results encourage the prodrug design targeting peptide transporters with great flexibility in chemical modification.
Peptide Transporter Associated Prodrug Therapy
As previously described, peptide transporters have broad substrate specificity and are a good target for prodrug development to improve oral drug absorption. As shown in Figure 3 , Amidon et al have developed the prodrug strategy targeting peptide transporters that is referred to as Peptide Transporter Associated Prodrug Therapy (PTAPT). A polar drug with low membrane permeability through passive diffusion is converted into a prodrug that is absorbed via the peptide transporter into the mucosal cell. This prodrug may still be very polar to assure sufficient solubility in the gastrointestinal lumen but may be well absorbed across the intestinal epithelium via the peptide transporters. Following membrane transport, the prodrug may be hydrolyzed by enzymes in the mucosal cell, blood, or liver. This prodrug strategy has been demonstrated to be effective for improving the membrane permeability and systemic availability of the polar a-methyldopa through peptidyl derivatives (43, 73) . The low membrane permeability of L-α α α α-methyldopa, which is poorly absorbed via Na+-coupled neutral amino acid transporter (74) , has been significantly improved by the peptidyl prodrugs such as Phe-α α α α-methyldopa, α α α α-methyldopa-Phe, and α α α α-methyldopa-Pro in rats, with absorption via peptide transporters (43, 73) . To minimize the extensive metabolism of L-dopa in the gut wall, tripeptide prodrugs of L-dopa, p-glu-L-dopa-pro were designed to be absorbed via peptide transporters and converted to L-dopa by peptidases (75) .
Recently, Amidon et al broadened the application of PTAPT to nonpeptidyl type prodrugs, such as amino acid ester prodrugs. They synthesized several amino acid ester prodrugs of the nucleoside antiviral drugs acyclovir and AZT and examined their intestinal absorption characteristics in 3 different experimental systems such as an in situ rat perfusion model, stably transfected CHO/hPEPT1 cells, and adenovirus mediated Caco-2/hPEPT1 cells (71, 72) . Amino acid ester prodrugs significantly (3-10 fold) increased the intestinal absorption of their parent drugs via a peptide transporter mediated mechanism, even though they do not have a peptide bond in their structures (Figures 4 and 5) . Following the membrane transport, these prodrugs were rapidly converted to the active parent drugs by intracellular hydrolysis (72) . These studies also demonstrated that the hPEPT1 transporter can recognize various amino acid progroups with stereoselectivity and that the nucleoside component can be varied. These results provide a new rationale for nonpeptidyl prodrug design targeting peptide transporters with great flexibility in structural modification. Recently, other research groups (76-79) have independently reported the peptide transporter-mediated membrane transport of the L-valylester prodrug of acyclovir (valacylovir) and confirmed the high potential of PTAPT in nonpeptidyl as well as peptidyl drug design. Consequently, PTAPT is a very useful strategy to improve the intestinal absorption of polar drugs.
CONCLUSIONS
The prodrug approach has been used to overcome various undesirable drug properties and to optimize the clinical drug application. Recent advances in molecular biology provide direct availability of enzymes and carrier proteins, including their molecular and functional characteristics. Thus prodrug design is becoming more elaborate in the development of efficient and selective drug delivery systems. Hence, prodrug design can no longer be considered as just a chemical modification to solve problems associated with drugs. The targeted prodrug approach, which can be combined with gene delivery and controlled expression of enzymes and carrier proteins, is a promising strategy for precise and efficient drug delivery and the enhancement of therapeutic efficacy. 
